Zszisław Sabiłło, president of the Polish Association of the Pharmaceutical Industry Employers (PZPPF), discusses the significance of the Polish generics market in terms of volume and sales market share, and highlights the obstacles that the generics ecosystem faces in light of the new reimbursement act. Furthermore, he provides insights into the introduction of biosimilars as well as the nation’s production capabilities and the steps being taken to promote future pharmaceutical investments into the Polish healthcare ecosystem.
As the president of the PZPPF, what is your mission?
"We must focus heavily on legislation and the amendments made to the reimbursement act in regard to ensuring the payback system is acceptable from an industry perspective."
